BiomX (NYSEAMERICAN:PHGE) Trading 9.9% Higher – Time to Buy?

BiomX Inc. (NYSEAMERICAN:PHGE)’s share price traded up 9.9% on Thursday . The company traded as high as $1.91 and last traded at $1.88. 70,220 shares were traded during mid-day trading, a decline of 46% from the average session volume of 130,091 shares. The stock had previously closed at $1.71.

Wall Street Analyst Weigh In

Separately, HC Wainwright upped their price target on BiomX to $26.00 and gave the stock a “buy” rating in a report on Tuesday, November 25th. One investment analyst has rated the stock with a Buy rating, Based on data from MarketBeat, BiomX presently has a consensus rating of “Buy” and an average price target of $26.00.

BiomX Trading Up 13.3%

The company has a market cap of $3.26 million, a price-to-earnings ratio of -0.08 and a beta of 1.56. The company has a fifty day moving average price of $6.75 and a two-hundred day moving average price of $8.36.

BiomX Company Profile

BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.